Cognoa, a digital health company focused on behavioral health for children, today announced FDA Breakthrough designations for it's first diagnostic and therapeutic devices to identify and treat autism. This is the foundation for its AI-based digital precision health to support the developmental and behavioral health of children, combining diagnostics and therapeutics into one platform. This signifies a big step in the company’s expansion into therapeutics.FDA Breakthrough Devices Program
Read More
Big Health Launches Digital Therapeutics App, Daylight to Improve Anxiety
Daylight is the first digital therapeutic to combine cognitive behavioral therapy, animation and the human voice to help people improve feelings of worry and anxiety. Digital therapeutics company Big Health today announced the launch of Daylight™, a scientifically rigorous yet approachable mobile app for reducing feelings of worry and anxiety. The Daylight app uses scientifically proven techniques based on cognitive behavioral therapy (CBT) to address feelings of worry and anxiety wherever and
Read More
M&A Analysis: 10 Reasons Why ResMed Acquired Propeller Health for $225M
On December 3rd, ResMed announced the acquisition of digital therapeutics maker Propeller Health for $225 million to help establish itself as a leader in COPD management across all stages of the disease. Digital medicines can help to personalize treatments, monitor patients in real-time, detect day-to-day changes in disease condition and increase patient adherence. Founded in 2010, Propeller helps people and their doctors better manage their COPD and asthma. Propeller’s digital medicine platform
Read More
ResMed to Acquire Propeller Health for $225M, Will Operate as Standalone Business
ResMed to acquire digital therapeutics maker Propeller Health for $225 million, establishing itself as a leader in COPD management.ResMed, a provider of cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has entered a definitive agreement to acquire digital therapeutics startup Propeller Health for $225M. For ResMed, the acquisition will help establish the company as a leader in COPD management across all stages of the
Read More
Force Therapeutics Raises $21M to Scale Episode-based Digital Care Delivery
Force Therapeutics, a New York-based provider of episode-based digital care delivery, today announced it has raised $21 million funding led by Insight Venture Partners. The funding will fuel Force's rapid product innovation, national expansion across major health systems, and client growth. Force is currently deployed in 60 facilities around the country and powers digital care management at leading health systems, including Geisinger, NYU Langone, Northwell Health, University Hospitals of
Read More
1DROP Raises $4.25M to Support Commercialization of Portable Medical Diagnostics Platform
1DROP, a life sciences startup developing and commercializing an easy to use laboratory quality, portable medical diagnostic testing platform has raised $4.25 million in Series A funding led by led by Christian Wildmoser (former partner CVC Capital Partners & Swiss Startup Group Investor). The round also included participation from private investors of the Swiss Startup Group including Dr. Hans-Peter Strebel (owner of On Your Marks), Beat Schillig (IFJ Institute for Young Entrepreneurs) and
Read More
WellSpan Health, Sweetch Partner to Deploy AI-Driven App for Diabetes Prevention
WellSpan Health partners with Sweetch to deploy its AI-based app to deliver large-scale prediction and prevention of diabetes to augment its employee wellness program.Diabetes is an epidemic, and our health systems are paying the price. With one in 11 adults affected globally and costs for people suffering from diabetes over 2x higher than those without the disease, it’s a pressing issue – and the latest technologies can help alleviate it.Today, integrated healthcare system WellSpan Health
Read More
Modis Therapeutics Raises $30M for Developing Medicines for Patients with Rare Genetic Diseases
Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases has raised $30 million in Series A funding led by F-Prime Capital Partners and OrbiMed. Joshua Grass, former F-Prime Entrepreneur-in-Residence and head of Corporate Development at BioMarin Pharmaceutical, has joined as President and Chief Executive Officer. Founding investor Aceras Life Sciences, LLC and new investor Osage University Partners also participated in the financing.Founded in 2016, Modis
Read More
Biotech Startup uBiome Raises $83M to Expand World’s Largest Human Microbiome Database
uBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led by OS Fund, with participation from 8VC, Y Combinator, Dentsu Ventures, and additional new and existing investors. Now, uBiome is mining its database (the world's largest human microbiome database) to discover new therapeutic targets, with an initial focus on
Read More
Click Therapeutics Lands $17M to Advance Prescription Digital Therapeutics Platform
Click Therapeutics, Inc. (“Click”), a provider of Digital Therapeutics solutions as prescription medical treatments, has raised $17 million in funding led by Sanofi Ventures, the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are rare diseases, vaccines, potential cures in other core areas of Sanofi’s
Read More